Vance DeGeneres

Stealth BioTherapeutics Announces Participation at Upcoming Ophthalmology Conferences

Retrieved on: 
星期三, 五月 1, 2024
FDA, Congress, AMD, Vance DeGeneres, Safety, OIS, Pharmacokinetics, The Company, Research, RWC, Stealth, ReNEW Schools, Paratriathlon, Season, ARVO, Pharmaceutical industry

At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Company will present a poster titled, "Next-generation Ocular Topical SBT-272 Demonstrates Optimized Retina Tissue Exposure: Building Upon Elamipretide for Treating Dry AMD."

Key Points: 
  • At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Company will present a poster titled, "Next-generation Ocular Topical SBT-272 Demonstrates Optimized Retina Tissue Exposure: Building Upon Elamipretide for Treating Dry AMD."
  • RWC is being held May 9-12 at the Fort Lauderdale Marriott Harbor Beach Hotel.
  • The upcoming presentations emphasize Stealth's commitment to develop its mitochondrial targeted investigational products to address the bioenergetic deficit contributing to disease pathology and vision loss in dry AMD.
  • Stealth is also advancing preclinical development of bevemipretide (SBT-272) for topical application, with Phase 1 initiation expected around year-end.

Eye health survey uncovers Canadians' concerns about recent symptoms affecting their eyes & vision: Canadian Ophthalmological Society

Retrieved on: 
星期三, 五月 1, 2024
Education, AMD, Vance DeGeneres, Cataract, Sport, Diabetic retinopathy, Diabetes, Artificial intelligence, Eye, Screen time, Paratriathlon, Hockey, Eye injury, Glaucoma, Agriculture

TORONTO, May 1, 2024 /CNW/ - In time for Vision Health Month this May, the Canadian Ophthalmological Society, the national authority on eye and vision care in Canada, has released a new survey to assess Canadians' awareness, understanding, and concerns around eye and vision health.

Key Points: 
  • TORONTO, May 1, 2024 /CNW/ - In time for Vision Health Month this May, the Canadian Ophthalmological Society, the national authority on eye and vision care in Canada, has released a new survey to assess Canadians' awareness, understanding, and concerns around eye and vision health.
  • Of the four leading eye diseases affecting vision, cataracts and glaucoma are still the most commonly known among Canadians.
  • "While the survey reveals increased awareness, it also highlights significant concerns and alarming symptoms experienced by Canadians over the past two years, emphasizing the necessity for comprehensive eye health education and regular eye exams."
  • To learn more about the four major eye diseases and get information on overall eye health, visit seethepossibilities.ca.

Luxa Biotechnology Awarded $4 Million CIRM Grant to Support Clinical Trial of Adult RPESC-RPE-4W Therapy for Dry Age-related Macular Degeneration

Retrieved on: 
星期三, 五月 1, 2024
Stem Cells, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Optical, Other Science, Research, Science, Clinical Trials, AMD, Vance DeGeneres, Cell, Hope, Doctor of Philosophy, Transplant, NSCI, CIRM, Patient, Paratriathlon, RPE, Quality of life, Therapy, Visual impairment

RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells (RPESC) that generate retinal pigmented epithelium (RPE) cell progeny (RPESC-RPE).

Key Points: 
  • RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells (RPESC) that generate retinal pigmented epithelium (RPE) cell progeny (RPESC-RPE).
  • Transplantation of progenitor-stage RPESC-RPE cells obtained after four weeks of differentiation (RPESC-RPE-4W) effectively replace the native RPE cells lost during AMD disease progression.
  • "We are honored to have CIRM recognize the potential of our unique technology utilizing precursor-stage RPE cells.
  • “RPESC-RPE-4W therapy represents a potential breakthrough in the treatment of dry AMD,” said Dr. Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM.

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
星期二, 三月 26, 2024
Research, Corporation, Conference, DLB, Alzheimer's disease, Disease, Biomarker, Public expenditure, Translational Neurodegeneration, Completeness, Vance DeGeneres, Protein, Clinical trial, Quantitative electroencephalography, Therapy, NIA, SHIMMER, Cognition, Pharmaceutical industry

PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Management will host a live webcast conference call at 8:00am ET to review 2023 accomplishments. Details of the call are provided below.

Key Points: 
  • ET -
    PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Cognition scientists published two manuscripts and made 11 presentations at medical and scientific congresses in 2023, advancing the understanding of its foundational science and clinical implications.
  • “We achieved a number of critical clinical objectives in 2023,” said Lisa Ricciardi, Cognition’s president and CEO .
  • Management will host a conference call and live webcast to discuss Cognition’s financial results today at 8:00 a.m.

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

Retrieved on: 
星期四, 四月 4, 2024
Health, FDA, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Medication, Survival, Wolfram syndrome, ALS, Partnership, Metabolism, Patient, AMX0035, Research, American Academy, OLE, Tauopathy, Health Canada, Biology, AAN, Clinical trial, Endoplasmic reticulum, Palsy, Workforce, Amylyx Pharmaceuticals, Division, Publication, Food, Vance DeGeneres, Pharmaceutical industry

Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.

Key Points: 
  • Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.
  • At this time, Amylyx intends to continue to collect available data on survival at the encouragement of ALS specialists.
  • “Our pipeline is supported by compelling clinical and preclinical science demonstrating the potential of AMX0035 and AMX0114 in neurodegenerative diseases.
  • “We are so thankful and grateful to our Amylyx team for their contributions and steadfast dedication,” said Cohen and Klee.

Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference

Retrieved on: 
星期四, 二月 15, 2024
Biotechnology, Pharmaceutical, Health, Neurology, Steps, ALS, Vance DeGeneres, Conference, Safety, Muscular Dystrophy Association, AMX0035, Pharmacokinetics, Abstract, Amylyx Pharmaceuticals, PB, Medication, MDA, Axon, Episcopal conference, Pharmaceutical industry

AMX0035 is marketed by Amylyx as RELYVRIO® and is approved to treat ALS in adults in the U.S. and approved with conditions as ALBRIOZA™ for the treatment of ALS in Canada.

Key Points: 
  • AMX0035 is marketed by Amylyx as RELYVRIO® and is approved to treat ALS in adults in the U.S. and approved with conditions as ALBRIOZA™ for the treatment of ALS in Canada.
  • This poster shares details on pre-clinical efficacy studies as well as introduces the design approach for the first-in-human study, anticipated to begin later this year.
  • The Company is studying multiple cellular pathways implicated in disease pathogenesis as we believe that it is going to take a combination approach to find a cure for ALS.
  • Additional information, including copies of the poster presentations, will be made available on the “ Publications ” tab of the Amylyx website, following the conclusion of the poster presentations.

EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting

Retrieved on: 
星期二, 二月 13, 2024
Biotechnology, Optical, Health, Clinical Trials, Therapy, Research, Retina, Doctor of Philosophy, Vance DeGeneres, OCT, Inflammation, Consultant, Diabetic retinopathy, VEGF, Patient, DME

The presentation of Week 12 data from AMARONE demonstrated that Restoret was well-tolerated, with no drug-related adverse events, drug-related serious adverse events, or intraocular inflammation reported.

Key Points: 
  • The presentation of Week 12 data from AMARONE demonstrated that Restoret was well-tolerated, with no drug-related adverse events, drug-related serious adverse events, or intraocular inflammation reported.
  • Similar outcomes were observed in patients with NVAMD (n=5), who received Restoret in combination with aflibercept.
  • The data demonstrated that multiple monthly doses of Restoret, as both monotherapy and in combination with aflibercept, were well-tolerated.
  • “These data from AMARONE are unique and impressive,” stated Charles C. Wykoff, MD, PhD.

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
星期四, 二月 8, 2024
Human, Inflammation, Survival, ALS, Athira Pharma, Pathology, Sympathetic nervous system, Frontiers, Vance DeGeneres, AFL, HGF, Doctor of Philosophy, Neuromuscular junction, Plasma, Research, Biomarker

ATH-1105 is a next-generation, orally administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.

Key Points: 
  • ATH-1105 is a next-generation, orally administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.
  • “These data demonstrate that ATH-1105 treatment results in significant, consistent beneficial effects both in cell culture and in vivo models of ALS.
  • “There is an urgent need for new ALS treatment options, particularly those aimed at slowing or stopping neurodegeneration,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
  • These findings further support our plans to progress ATH-1105 into first-in-human studies in the first half of 2024.”

RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS

Retrieved on: 
星期二, 一月 16, 2024
Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Therapy, Vance DeGeneres, FACS, University, AMD

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results showing retinal structure improvements with RG6501( OpRegen ) from a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) in geographic atrophy (GA) secondary to advanced age-related macular degeneration (AMD), will be presented at the 2024 Angiogenesis, Exudation, and Degeneration Meeting .

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results showing retinal structure improvements with RG6501( OpRegen ) from a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) in geographic atrophy (GA) secondary to advanced age-related macular degeneration (AMD), will be presented at the 2024 Angiogenesis, Exudation, and Degeneration Meeting .
  • The virtual meeting will be held February 3, 2024, and is sponsored by the University of Miami Health System Bascom Palmer Eye Institute .
  • The presentation, “Retinal Structure Improvements with OpRegen RPE Cell Therapy in a Phase I/IIa Study in Geographic Atrophy,” will be presented by Allen Ho , MD, FACS, FASRS, Co-Director, Wills Eye Retina Service and Director, Retina Research, Wills Eye Hospital on behalf of Roche and Genentech , a member of the Roche Group.

Cognition Therapeutics CEO Issues Letter to Shareholders

Retrieved on: 
星期四, 一月 4, 2024
Biology, Work, Geographic atrophy, SHIMMER, Alzheimer's disease, Dementia, Neuron, ACTC, Iris (anatomy), EEG, Lewy body, RPE, Antibody, Letter, AMD, Brain, Therapy, Clinical trial, ADAS, SPARC, Society, DLB, SHINE, Cognition, Vance DeGeneres, Biomarker, Toxicity, Optimism, Manuscript, Cell, Patient, Magnification, Synapse, Diagnosis, Safety, Pharmaceutical industry

PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024. The full text of the letter follows:

Key Points: 
  • PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024.
  • The full text of the letter follows:
    The year ahead holds great promise for Cognition Therapeutics.
  • As we work towards these important milestones, we take stock of the achievements that give rise to optimism at Cognition Therapeutics and in the broader medical community.
  • For Cognition, expanding the pipeline for CT1812 to dry AMD has the potential to grow Cognition’s value across multiple age-related diseases.